13F Pro

SEC Form 4 reporting owner

Boyce Sarah

Boyce Sarah has filed 15 Form 4 transactions reported between December 17, 2025 and September 18, 2026, as a reporting owner of Atrium Therapeutics, Inc., Director of Contineum Therapeutics, Inc. and President and CEO of Avidity Biosciences, Inc..

Name as filed: Boyce Sarah

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$1.7M
3 lines
Companies
3
with Form 4 filings
Latest transaction
Sep 18, 2026
transaction date

Roles and reported holdings

  • RNAAtrium Therapeutics, Inc.
    Sep 18, 2026

    Reporting owner

    Held directly138,668 sh as of Sep 18, 2026 · Form 4
  • CTNMContineum Therapeutics, Inc.
    Jun 26, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • RNAAvidity Biosciences, Inc.
    Dec 17, 2025 – Feb 27, 2026

    President and CEO

    Held directly269,007 sh as of Jan 21, 2026 · Form 4

    24 months: $1.7M sold

Transaction history

All 15 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Sep 18, 2026RNAShares withheld for tax or exercise priceCode F · direct126,418$1.1M@ $8.95Form 4
Jun 26, 2026CTNMDirectorGrant or awardCode A · direct19,000—Form 4
Feb 27, 2026RNAPresident and CEODisposition to issuerCode D · direct165,000—Form 4
Feb 27, 2026RNAPresident and CEODisposition to issuerCode D · direct200,000—Form 4
Feb 27, 2026RNAPresident and CEODisposition to issuerCode D · direct400,000—Form 4
Feb 27, 2026RNAPresident and CEODisposition to issuerCode D · direct425,000—Form 4
Feb 27, 2026RNAPresident and CEODisposition to issuerCode D · direct300,000—Form 4
Feb 27, 2026RNAPresident and CEODisposition to issuerCode D · direct386,015—Form 4
Feb 27, 2026RNAPresident and CEODisposition to issuerCode D · direct474,861—Form 4
Jan 21, 2026RNAPresident and CEOOpen-market saleCode S · direct7,993$579K@ $72.45Form 4
Jan 21, 2026RNAPresident and CEOOpen-market saleCode S · direct6,394$463K@ $72.45Form 4
Jan 7, 2026RNAPresident and CEOOpen-market saleCode S · direct8,576$619K@ $72.23Form 4
Dec 18, 2025RNAPresident and CEOGiftCode G · direct29,159—Form 4
Dec 17, 2025RNAPresident and CEOShares withheld for tax or exercise priceCode F · direct15,742$1.1M@ $71.87Form 4
Dec 17, 2025RNAPresident and CEOGrant or awardCode A · direct31,000—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.